Case Western Reserve Scientists Discover Novel Molecular Target for Parkinson’s Disease
Researchers at Case Western Reserve University have discovered a new biochemical pathway that could lead to treatments targeting the underlying causes of Parkinson’s disease.
The chronic neurological disorder affects around 1 million Americans, with approximately 90,000 new cases each year, and is caused by the degeneration of dopamine-producing neurons responsible for coordinated movement.
The team’s findings, published in Molecular Neurodegeneration, show that the toxic protein alpha-synuclein interacts with the enzyme ClpP, damaging mitochondria—the energy-producing structures in brain cells—and causing neuron death. This harmful interaction contributes to the progression of Parkinson’s disease.
To overcome this, the researchers developed CS2, a novel treatment designed to block the damaging protein interaction. Acting like a decoy, CS2 redirects alpha-synuclein away from mitochondria, restoring their function.
In preclinical studies, including patient-derived neurons, human brain tissue and mouse models, CS2 improved motor and cognitive performance and reduced brain inflammation.
The work represents a shift from symptom management to addressing a fundamental cause of the disease.
The team plans to advance CS2 toward clinical trials over the next five years, focusing on optimisation for human use, safety and efficacy testing, and identification of molecular biomarkers.
This discovery highlights the potential for mitochondria-targeted therapies to protect neurons and improve quality of life for people living with Parkinson’s disease, offering hope for a future in which the condition becomes manageable or even preventable.
